Chemonucleolysis with Chondroitin Sulfate ABC Endolyase for Treating Lumbar Disc Herniation: Exploration of Prognostic Factors for Good or Poor Clinical Outcomes

Chemonucleolysis with Chondroitin Sulfate ABC Endolyase for Treating Lumbar Disc Herniation: Exploration of Prognostic Factors for Good or Poor Clinical Outcomes

<i>Background and Objectives:</i> Chondroitin sulfate ABC endolyase (condoliase) was launched as a new drug for chemonucleolysis in 2018. Few studies assessed its clinical outcomes, and many important factors remain unclear. This study aimed to clarify the preoperative conditions in whic...

Full description

Bibliographic Details
Main Authors: Katsuhiko Ishibashi, Muneyoshi Fujita, Yuichi Takano, Hiroki Iwai, Hirohiko Inanami, Hisashi Koga
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Medicina
Subjects:
chemonucleolysis
condoliase
chondroitin sulfate ABC endolyase
lumber disc herniation
Online Access:https://www.mdpi.com/1010-660X/56/11/627

Internet

https://www.mdpi.com/1010-660X/56/11/627

Similar Items